Kornimate/medical-research-clean huggingface dataset:
atrial fibrillation patient preference study

Conditions: Atrial Fibrillation

Summary: the main research question of this patient survey is to assess af patients' preferences associated with different attributes which describe the different available anticoagulation treatment options (vka or noacs and, in case of noacs, apixaban, dabigatran or rivaroxaban). vka (waran®) will be compared to rivaroxaban.

the objective of this study is to investigate the following research questions in a cross-sectional survey of swedish af patients being treated either with a vka or with a noac: * which attributes of a medication to prevent stroke do af patients view as important? * do af patients have a preference regarding the attributes of the medication options vka or noac and, in case of noacs, with regards to rivaroxaban attributes? * are there subgroups of af patients whose preference for one of the medication options appears above or below average? * what is the quality of life of swedish af patients? are there subgroups with differences in their quality of life (for example: subgroups of patients with different cha2ds2-vasc scores)? * which burden do swedish af patients experience in association with their anticoagulation therapy? are there differences in the burden of treatment (acts) between patients treated with vka or with noacs?

Eligibility criteria:
inclusion criteria: inclusion criteria for af patients in both the noac and the vka groups: * patients with a confirmed diagnosis of nonvalvular atrial fibrillation (persistent, paroxysmal, permanent), * age of at least 18 years at time of study inclusion, * generally willingness (informed consent) and ability to fill out a survey on satisfaction with treatment and quality of life, and to conduct a structured phone interview (approx. 20 - 30 min) in swedish language. additional inclusion criterion for group 1 (noac): * continuous anticoagulation with either apixaban, or dabigatran or rivaroxaban for prevention of stroke \& systemic embolism for at least the previous 3 months. additional inclusion criterion for group 2 (vka): * continuous anticoagulation with a vka for prevention of stroke \& systemic embolism for at least the previous 3 months. exclusion criteria: exclusion criteria for both groups: * participation in another

Keywords: non-valvular atrial fibrillation patient treatment preference noac vka
clinical characteristics of critically ill patients with covid-19

Conditions: Coronavirus Infection; Critical Illness; Characteristics Disease

Summary: critically ill patients with covid-19 have hospitalized in an icu due to the closer monitoring and therapy. in fact, icu admissions are dependent on the severity of illness and the icu capacity of the health-care system. hence, it may be need a new scoring system for contagious critically ill patients.

critically ill patients with covid-19 have hospitalized in an icu due to the closer monitoring and therapy. in fact, icu admissions are dependent on the severity of illness and the icu capacity of the health-care system. therefore, many patients with confirmed covid-19 with rt-pcr and/or suspected covid-19 were hospitalized in icus with a limited number of beds. this ambiguity can result in both contamination risk to uninfected patients and occupancy rate of the limited icu beds. hence, it may be need a new scoring system for contagious critically ill patients. the aim of this study was to describe the epidemiological and clinical features of 75 critically ill patients due to covid-19 and to compare confirmed covid-19 cases with suspected covid-19 cases in our critical care units.

Eligibility criteria:
inclusion criteria: * all patients with confirmed covid-19 and suspected covid-19 exclusion criteria: * all patients \<18 years old
in-human cxcr4 imaging of hematologic and solid tumors using [68ga]-pentixafor-pet

Conditions: Non-Hodgkin Lymphoma; Multiple Myeloma; Histiocytic Neoplasms; Erdheim-Chester Disease; Rosai-Dorfman Disease

Summary: the purpose of this study is to determine the uptake of the imaging agent \[68ga\]-pentixafor with pet/ct scans in people with monoclonal gammopathy of undetermined significance (mgus), smoldering multiple myeloma (smm), and non-hodgkin lymphoma (nhl), or you have histiocytic neoplasms (langerhans cell histiocytosis (lch), erdheim-chester disease (ecd) and/or rosai-dorfman disease (rdd).


Eligibility criteria:
inclusion criteria: twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included: * indolent b- or t-cell non-hodgkin lymphoma (including cutaneous lymphomas) or non-hodgkin lymphoma with variable fdg uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to lugano criteria or * histiocytic neoplasms (langerhans cell histiocytosis (lch), erdheim-chester disease (ecd) and/or rosai-dorfman disease (rdd) * mgus/smm or mm according to imwg definitions * solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with cushing's disease. * age ≥18 * negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by mskcc standards \& guidelines) from assays obtained \<2 weeks prior to study enrollment/intervention; or negative urine pregnancy test performed on the day of intervention * mskcc patients exclusion criteria: * breast-feeding * history of renal functional disorders (chronic kidney disease with egfr\<30) * refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)

Keywords: [68ga]-pentixafor pet/ct scan in-human cxcr4 imaging 21-356 symptomatic multiple myeloma pre-cursor myeloma mgus smm memorial sloan kettering cancer center
big data and genomic imaging for the development of biomarkers and nanovector drugs innovative for diagnosis and therapy of inflammatory processes in dementia

Conditions: Neurodegenerative Diseases

Summary: the correlation between data obtained by "imaging" in patients with neurodegenerative diseases characterized by inflammation and the presence in the peripheral blood of the same patients "biopsies liquid biopsies" of specific circulating nucleic acids, could enable the development of methods and algorithms capable of identifying novel biomarkers that serve as targets for the development of probes diagnostics and therapeutics. this is the context for the project idea, which is aimed at developing development of a performant multi parameter system capable of identifying novel biomarkers of microglial polarization that can be used for diagnostic and prognostic purposes in determining the staging/progression of neurodegenerative disease


Eligibility criteria:
inclusion criteria: all subjects of either sex aged 18 to 85 years who are able to provide voluntary consent, suffering from neurodegenerative diseases (ad and pd) exclusion criteria: all patients for whom there are contraindications to performing mri. also excluded from the study will be subjects who are pregnant, or presumed to be pregnant or undergoing of lactation and subjects with claustrophobia
the detection of circulating tumor cells (ctcs) in patients with liver cancer undergoing cryosurgery combined with dc-cik treatment

Conditions: Neoplastic Cells, Circulating

Summary: circulating tumor cells (ctcs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. enumeration and molecular characterization of ctcs in liver cancer could play an important role in diagnosis, predicting the risk for tumor recurrence, and providing novel target therapy biomarkers. in view of these facts, the investigators wanted to demonstrate the value of multiparameter flow cytometry in detecting human tumor cells of liver cancer in normal peripheral blood after cryosurgery with or without dendritic cell(dc)-cytokine-induced killers(cik) treatment, and the investigators also compared the specificity with reverse transcriptase polymerase chain reaction (rt-pcr) method.

1 day before and 2 days after cryosurgery with or without dc-cik treatment，approximately 17-ml ethylene diamine tetraacetic acid(edta)-blood was drawn by vein puncture from patients with liver cancer and healthy volunteers. the blood of the healthy volunteers will be used to evaluate the sensitivity and specificity and as negative control cells. to avoid contamination with skin cells, 2 ml blood will be discarded before the study samples will be taken.briefly, the mononucleate cells will be separated from the blood over ficoll- paque for 20 min with 1800g at 4℃. the interface cells will be removed and washed, and the red blood cells(rbcs) will be removed using a lysis buffer followed by a repeated wash. the mononuclear cells will be counted and aliquot for rt-pcr and multiparameter flow cytometry on the basis of at least 2-3×106 cells for each methodology. the cell pellet will be resuspended in phosphate-buffered saline for multiparameter flow cytometry and in trizol reagent for rt-pcr. aim : identification of ctcs may lead to better diagnosis and prognosis and could help to choose an adequate therapy.

Eligibility criteria:
inclusion criteria: 1. age:18-75 2. karnofsky performance status \>60 3. diagnosis of liver cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive cryosurgery and/or dc-cik treatment 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except liver cancer 2. history of coagulation disorders or anemia

Keywords: liver neoplasms circulating tumor cells
xingnaojing for mild-to-severe acute ischemic stroke

Conditions: Acute Ischemic Stroke; Stroke, Acute; Stroke, Ischemic

Summary: the main purpose of this trial is to determine whether xingnaojing, intravenously administered within 24 hours of symptom onset, improves the daily living ability of acute ischemic stroke at 90 days.

the xmas-2 study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. the primary hypothesis of this trial is that xingnaojing will improve the daily living ability of acute ischemic stroke at 90 days. xingnaojing will be compared to placebo, combined with guidelines-based standard care in patients with acute ischemic stroke within 24 hours of symptom onset. all participants will have a national institutes of health stroke scale(nihss)entry score of 4-25. participants who have planned or already received the intravenous thrombolysis or endovascular treatment will be excluded. the primary outcome will be determined at 90 days.

Eligibility criteria:
inclusion criteria: * diagnosis of acute ischemic stroke； * symptom onset within 24 hours； * age ≥ 18 and ≤ 80 years； * nihss score ≥ 4 and ≤ 25； * patient or legally authorized representative has signed informed consent. exclusion criteria: * planned or already receiving intravenous thrombolysis or endovascular treatment; * suspected secondary stroke caused by tumor, brain trauma, or hematological diseases; * already dependent in activities of daily living before the present acute stroke (defined as modified rankin scale score ≥ 2) ; * other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease); * other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis); * significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (alt), or aspartate aminotransferase (ast) value that is twice the upper limit of normal); * life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer) * other conditions that render outcomes or follow-up unlikely to be assessed; * known to be pregnant or breastfeeding; * currently receiving an investigational drug;

Keywords: acute ischemic stroke xingnaojing injection traditional chinese medicine double-blind randomized controlled trial
multiomics tumor evolution model of nsclc

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

lung cancer is the leading cause of cancer-related death globally. non-small cell lung cancer (nsclc) accounts for 85% of lung cancer and surgery is still the main treatment strategy. this study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. early-stage nsclc patients underwent radical surgical resection; 3. sufficient tumor tissue and blood sample for study use; 4. available clinical-pathologic data, imaging data and follow-up date; 5. written informed consent. exclusion criteria: 1. history of other malignant tumors; 2. evidence of distant metastasis before surgery; 3. insufficient tumor tissue or blood sample for study use; 4. clinical-pathologic data, imaging data or follow-up date is not available; 5. other judgments by the investigator that the patient should not participate in the study.

Keywords: non-small cell lung cancer multiomics analysis tumor evolution tumor immune microenvironment circulating tumor dna radiomics prognostic model
three different cross-linking protocols for treatment of pediatric keratoconus

Conditions: Corneal Ectasia

Summary: comparison between standard cross-linking protocol and accelerated and transepithelial cross-linking

comparison between standard cross-linking protocol and accelerated and transepithelial cross-linking for treatment of documented pediatric keratoconus progression. the study patients are divided into 3 groups. group a patient treated with standard cross-linking. group b patients treated with accelerated cross-linking. group c patients treated with transepithelial cross-linking.

Eligibility criteria:
inclusion criteria: * pediatric patient less than 18 years old * keratoconus stage i-iii abcd keratoconus grading system exclusion criteria: * age more than 18 years * previous eye surgery * current eye infection or pathology
filgotinib in long-term extension study of adults with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (uc).


Eligibility criteria:
key inclusion criteria: * must have the ability to understand and sign a written informed consent form (icf), which must be obtained prior to initiation of study procedures associated with this trial * must have enrolled in gilead-sponsored uc parent protocol gs us 418-3898 or any other gilead/galapagos-sponsored filgotinib treatment study for uc * must have completed all required procedures or met protocol-specified efficacy discontinuation criteria in a prior filgotinib treatment study for uc * females of childbearing potential must have a negative pregnancy test at day 1 * female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception for the duration described * willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug key exclusion criteria: * known hypersensitivity to the study drug * any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the investigator or sponsor, would make the subject unsuitable for the study or would prevent compliance with the study protocol * females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined * use of prohibited medications as outlined in the protocol note: other protocol defined inclusion/ exclusion criteria may apply.
to evaluate the safety, tolerability and pharmacokinetic properties of dwrx2003

Conditions: COVID-19 Patients

Summary: this study is designed to assess the safety, tolerability and pharmacokinetic properties of niclosamide injectable (dwrx2003) in healthy volunteers.


Eligibility criteria:
inclusion criteria: 1. healthy males and females, between 18 and 65 years of age, inclusive, at time of signing the informed consent form (icf). 2. body mass index between 18.0 lesser than or equal to body mass index (bmi) lesser than or equal to 32 at screening, with a minimum weight of 50 kg (inclusive). 3. willing to sign icf on a voluntary basis and to voluntarily participate in the study, after being fully informed of and completely understanding this study, prior to any screening procedure being undertaken exclusion criteria: 1. pregnant or lactating at screening or planning to become pregnant (self or partner) at any time during the study, including the follow-up period; 2. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee). please note participants with allergies which can be managed without treatment can be included based on the decision of the investigator (or designee). 3. significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee)
china tongxinluo study for myocardial protection in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: to determine the therapeutic effects of tongxinluo capsules as compared with placebo in the treatment of patients with acute st-elevation myocardial infarction (stemi): (1) clinical efficacy and safety at 30 days: the incidence of composite endpoints comprising major adverse cardiovascular and cerebrovascular events (macce, including cardiovascular death, myocardial re-infarction, emergency coronary revascularization and cerebral stroke), severe complications (including cardiogenic shock, heart failure, mechanical complications and malignant arrhythmias), and major bleeding (barc grade iii and v); (2) clinical efficacy and safety at 1 year: the incidence of composite endpoints comprising macce, hospitalization due to heart failure, in-stent thrombosis, and major bleeding (barc grade iii and v), as well as all-cause mortality; (3) the effects in promoting myocardial reperfusion, reducing incidence of myocardial no-reflow, protecting ischemic myocardium, minimizing infarction size, and improving left ventricular systolic function.


Eligibility criteria:
inclusion criteria: 1. age\>18 years; 2. within 24 hours of infarctional chest pain onset; 3. ecg shows st-segment elevation ≥0.2mv in more than 2 adjacent leads, or new left bundle branch block (lbbb); 4. voluntary participation in the study with consent forms signed. exclusion criteria: 1. critically illness due to stemi; 2. long-term (\>20 min) cardio-pulmonary resuscitation (cpr); 3. suspected aortic dissection or acute pulmonary embolism; 4. explicit mechanical complications, including interventricular septum perforation, rupture of papillary muscles and chordae tendineae, or on-going or ruptured left ventricular free walls. 5. serious cardiogenic shock and do not responding to hypertensive agents; 6. uncontrolled acute left heart failure or pulmonary edema; 7. malignant arrhythmias uncontrolled by anti-arrhythmia agents; 8. bleeding history of cerebral vessels, gastrointestinal tract, respiratory tract, urinary tract or other organs within 1 month; 9. presence of active hemorrhage at any part of the body (including menstruation); 10. known hemorrhagic constitution or serious hemostasis and blood coagulation disorders; 11. current usage of anticoagulants (such as warfarin or new anticoagulants); 12. . serious hepatorenal dysfunction \[atl≥5 uln (upper limit of normal), cr\>134μmol/l (2mg%) or egfr\<45ml/min/1.73m2\]; 13. serious chronic obstructive pulmonary disease (copd) or respiratory failure; 14. . severe infection: 15. . very weak or frailty; 16. . neuropsychiatric system diseases; 17. . malignancies; 18. . other pathophysiological conditions with expected survival time \<1 year; 19. allergy to the ingredients of this investigational drug; 20. women who are in pregnancy or nursery; 21. participation in clinical study of other traditional chinese medicine (tcm); 22. unsuitability to participate in this study due to other diseases.
retrospective review of integrity implants flarehawk® for lumbar fusion

Conditions: Degenerative Disc Disease

Summary: this is a retrospective clinical study (chart review) of patients who have previously undergone transforaminal lumbar interbody fusion or posterior lumbar interbody fusion surgery with the flarehawk expandable interbody fusion cage at one or two contiguous levels.

the purpose of this study is to evaluate the clinical outcomes of patients who have undergone a transforaminal lumbar interbody fusion (tlif) or posterior lumbar interbody fusion (plif) procedure with a flarehawk expandable interbody fusion cage(s) to assess the device's performance and safety when used in accordance with its intended use. the primary hypothesis is that study subjects who received the flarehawk expandable cage(s) through a tlif or plif procedure experienced fusion by 12 months (+/- 3 mo) follow-up, with improvements in clinical outcomes related to pain and/or disability compared to pre-operative scores. further, the subjects are hypothesized to have not experienced any unforeseen device- or procedure-related adverse events.

Eligibility criteria:
inclusion criteria: to be a part of this study, the subject must: 1. have been at least 18 years of age and skeletally mature at the time of surgery 2. have had clinical and radiological evidence of degenerative disc disease of the lumbar spine 3. have been treated with plif or tlif surgery using the flarehawk expandable interbody cage(s) at 1 or 2 contiguous levels from l2 to s1 4. have been treated using the flarehawk expandable interbody fusion cage, according to the approved labeling, between december 1, 2017, and may 31, 2018 exclusion criteria: subjects must not meet any of the following exclusion criteria to be included in the study: 1. have a history of fusion surgery at the study level(s) prior to treatment with the flarehawk device(s) 2. have had spondylolisthesis unable to be reduced to grade 1 as part of the surgical procedure 3. have had surgery with the flarehawk device(s) at more than 2 levels 4. have had surgery with the flarehawk device(s) at levels outside the range of l2 to s1 5. have been treated with any bone grafting material other than autogenous or allogenic bone graft in the flarehawk device(s) and surrounding disc space 6. have any contraindications listed in the approved labeling